Cough In Idiopathic Pulmonary Fibrosis Market: By Drug (Pirfenidone, Nintedanib, Interferon gamma-1b, and Others), By Route of Administration (Oral, Parenteral), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) and Geography

Cough In Idiopathic Pulmonary Fibrosis Market size was valued at USD x million in 2023 and is poised to grow at a CAGR  of x% from 2024 - 2030. The cough in Idiopathic Pulmonary Fibrosis (IPF) market refers to the prevalence, impact, and treatment landscape of cough as a symptom in patients diagnosed with IPF. Idiopathic Pulmonary Fibrosis is a progressive and debilitating lung disease characterized by the scarring of lung tissues, leading to decreased lung function and impaired gas exchange. Among the prominent symptoms experienced by IPF patients, chronic cough is one of the most distressing and persistent manifestations, significantly affecting their quality of life.

According to World Health Organization (WHO) and the Centers for Disease Control and Prevention (CDC) 2021, it was estimated that IPF affected approximately 3 million people worldwide, with an increasing prevalence in older age groups. The mortality rate of IPF was reported to be around 50,000 to 70,000 deaths annually in the United States alone. Research indicated that up to 80% of IPF patients experience a chronic cough, leading to sleep disturbances, physical limitations, and a reduced ability to perform daily activities. Moreover, cough-related complications, such as fractures, can further deteriorate the patients' health. Treatment options for cough in IPF vary depending on the severity of the symptom and the overall disease progression. Medications like antitussives and corticosteroids are commonly prescribed to manage cough in IPF patients.

However, the limited effectiveness of these treatments underscores the need for novel therapies targeting the underlying mechanisms of IPF and its associated cough. To develop more effective interventions, ongoing research, and clinical trials focus on understanding the pathophysiology of cough in IPF and identifying potential therapeutic targets. The market for IPF treatments is expected to witness significant growth in the coming years, driven by advancements in medical science and the increasing awareness of this rare but devastating condition.

Cough In Idiopathic Pulmonary Fibrosis Market Key Developments:

• In July 2022, PureTech, a biotechnology company, announced the initiation of the clinical trial to evaluate the safety and efficacy of LYT-100, (oral drug) as compared to pirfenidone or placebo in adults with Idiopathic Pulmonary Fibrosis. The clinical trial is currently in phase 2 and is actively recruiting.
• In September 2020, FibroGen a biotechnology company, announced the initiation of a clinical trial to evaluate the efficacy and safety of 30 milligrams (mg)/kilogram (kg) intravenous (IV) infusions of Pamrevlumab in participants with Idiopathic Pulmonary Fibrosis (IPF). This clinical trial is currently in phase 3 and is actively recruiting.